$2.28
2.70% today
Nasdaq, Aug 22, 10:07 pm CET
ISIN
CA4576375022
Symbol
INM

InMed Pharmaceuticals Inc Stock price

$2.28
-0.37 13.96% 1M
-0.72 24.00% 6M
-2.46 51.90% YTD
-5.95 72.30% 1Y
-182.12 98.76% 3Y
-2,247.77 99.90% 5Y
-2,456.22 99.91% 10Y
-371,247.72 100.00% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.06 2.70%
ISIN
CA4576375022
Symbol
INM
Industry

Key metrics

Basic
Market capitalization
$4.4m
Enterprise Value
$-280.0k
Net debt
positive
Cash
$4.7m
Shares outstanding
1.2m
Valuation (TTM | estimate)
P/E
negative | -
P/S
0.9 | 0.1
EV/Sales
negative | negative
EV/FCF
0.0
P/B
0.6
Financial Health
Equity Ratio
77.9%
Return on Equity
-83.4%
ROCE
-108.7%
ROIC
-202.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.9m | $6.8m
EBITDA
$-7.7m | -
EBIT
$-8.1m | -
Net Income
$-8.3m | -
Free Cash Flow
$-7.0m
Growth (TTM | estimate)
Revenue
-12.5% | 47.2%
EBITDA
-19.9% | -
EBIT
-21.7% | -
Net Income
-36.7% | -
Free Cash Flow
-3.5%
Margin (TTM | estimate)
Gross
32.4%
EBITDA
-156.6% | -
EBIT
-164.3%
Net
-168.9% | -
Free Cash Flow
-142.6%
More
EPS
$-7.6
FCF per Share
$-5.8
Short interest
4.1%
Employees
13
Rev per Employee
$350.0k
Show more

Is InMed Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

InMed Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a InMed Pharmaceuticals Inc forecast:

3x Hold
38%
5x Sell
63%

Analyst Opinions

8 Analysts have issued a InMed Pharmaceuticals Inc forecast:

Hold
38%
Sell
63%

Financial data from InMed Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4.92 4.92
12% 12%
100%
- Direct Costs 3.33 3.33
3% 3%
68%
1.60 1.60
27% 27%
33%
- Selling and Administrative Expenses 5.52 5.52
1% 1%
112%
- Research and Development Expense 3.79 3.79
19% 19%
77%
-7.71 -7.71
20% 20%
-157%
- Depreciation and Amortization 0.38 0.38
81% 81%
8%
EBIT (Operating Income) EBIT -8.08 -8.08
22% 22%
-164%
Net Profit -8.31 -8.31
37% 37%
-169%

In millions USD.

Don't miss a Thing! We will send you all news about InMed Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

InMed Pharmaceuticals, Inc. engages in the research and development of cannabinoid-based therapies and biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It offers pipeline of medications that target diseases with unmet medical needs, such as epidermolysis bullosa, glaucoma, and orofacial pain. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Eric Adams
Employees 13
Founded 1981
Website www.inmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today